EG24401A - Mesylate. Trihydrate of. 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-ine - Google Patents

Mesylate. Trihydrate of. 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-ine

Info

Publication number
EG24401A
EG24401A EG37797A EG37797A EG24401A EG 24401 A EG24401 A EG 24401A EG 37797 A EG37797 A EG 37797A EG 37797 A EG37797 A EG 37797A EG 24401 A EG24401 A EG 24401A
Authority
EG
Egypt
Prior art keywords
benzisothiazole
ine
trihydrate
indol
mesylate
Prior art date
Application number
EG37797A
Other languages
English (en)
Inventor
R Busch Frank
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of EG24401A publication Critical patent/EG24401A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EG37797A 1996-05-07 1997-05-04 Mesylate. Trihydrate of. 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-ine EG24401A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1653796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
EG24401A true EG24401A (en) 2009-04-29

Family

ID=21777622

Family Applications (1)

Application Number Title Priority Date Filing Date
EG37797A EG24401A (en) 1996-05-07 1997-05-04 Mesylate. Trihydrate of. 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-ine

Country Status (46)

Country Link
US (1) US6110918A (bg)
EP (1) EP0904273B1 (bg)
JP (1) JP3102896B2 (bg)
KR (1) KR100333214B1 (bg)
CN (1) CN1092658C (bg)
AP (1) AP838A (bg)
AR (1) AR007003A1 (bg)
AT (1) ATE236902T1 (bg)
AU (1) AU730856C (bg)
BG (1) BG63601B1 (bg)
BR (1) BR9708932A (bg)
CA (1) CA2252895C (bg)
CO (1) CO4940465A1 (bg)
CZ (1) CZ289216B6 (bg)
DE (1) DE69720719T2 (bg)
DK (1) DK0904273T3 (bg)
DZ (1) DZ2221A1 (bg)
EA (1) EA001180B1 (bg)
EG (1) EG24401A (bg)
ES (1) ES2192264T3 (bg)
GT (1) GT199700042A (bg)
HK (1) HK1017893A1 (bg)
HN (1) HN1997000040A (bg)
HR (1) HRP970235B1 (bg)
HU (1) HU229057B1 (bg)
ID (1) ID17504A (bg)
IL (1) IL126590A (bg)
IS (1) IS2301B (bg)
MA (1) MA26427A1 (bg)
ME (1) ME00901B (bg)
MY (1) MY128051A (bg)
NO (1) NO312513B1 (bg)
NZ (2) NZ508303A (bg)
OA (1) OA10908A (bg)
PL (1) PL188164B1 (bg)
PT (1) PT904273E (bg)
SI (1) SI0904273T1 (bg)
SK (1) SK282674B6 (bg)
TN (1) TNSN97073A1 (bg)
TR (1) TR199802241T2 (bg)
TW (1) TW427989B (bg)
UA (1) UA47467C2 (bg)
UY (1) UY24543A1 (bg)
WO (1) WO1997042190A1 (bg)
YU (1) YU49398B (bg)
ZA (1) ZA973875B (bg)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
DE69910706T2 (de) * 1998-05-26 2004-07-08 Pfizer Products Inc., Groton Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
GEP20053427B (en) * 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
NZ551012A (en) * 2000-06-02 2008-04-30 Pfizer Prod Inc Use of S-methyl-dihydro-ziprasidone administered via either the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal or topical routes in doses ranging from 0.5 to 500 mg per day
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
AU2003300814A1 (en) 2002-12-04 2004-06-23 Dr. Reddy's Laboratories Inc. Polymorphic forms of ziprasidone and its hydrochloride
BRPI0410378A (pt) * 2003-05-16 2006-06-13 Pfizer Prod Inc tratamento de distúrbios psicóticos e depressivos
JP2006528236A (ja) * 2003-05-16 2006-12-14 ファイザー・プロダクツ・インク ジプラシドンを用いて認知を増強する方法
MXPA05012392A (es) * 2003-05-16 2006-02-02 Pfizer Prod Inc Tratamientos de ansiedad con ziprasidona.
WO2005016325A2 (en) * 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd. CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
JP2007504266A (ja) * 2003-09-02 2007-03-01 ファイザー・プロダクツ・インク ジプラシドンの持続放出剤形
WO2005040160A2 (en) * 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
EP1592688A2 (en) * 2003-12-18 2005-11-09 Teva Pharmaceutical Industries Ltd. Polymorphic form b2 of ziprasidone base
CA2552126A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Ziprasidone formulations
ATE451367T1 (de) * 2004-02-27 2009-12-15 Ranbaxy Lab Ltd Verfahren zur herstellung von ziprasidon
US9044503B2 (en) * 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
US7910577B2 (en) * 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
CA2599391A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
WO2008143960A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
KR100948126B1 (ko) * 2007-12-10 2010-03-18 씨제이제일제당 (주) 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Also Published As

Publication number Publication date
SI0904273T1 (en) 2003-08-31
HK1017893A1 (en) 1999-12-03
HN1997000040A (es) 1997-06-05
PT904273E (pt) 2003-06-30
US6110918A (en) 2000-08-29
ATE236902T1 (de) 2003-04-15
IL126590A0 (en) 1999-08-17
TW427989B (en) 2001-04-01
UY24543A1 (es) 2000-09-29
CA2252895C (en) 2002-08-20
IS2301B (is) 2007-10-15
DZ2221A1 (fr) 2002-12-03
EA001180B1 (ru) 2000-10-30
SK282674B6 (sk) 2002-11-06
NZ508303A (en) 2001-07-27
BG102893A (bg) 1999-09-30
AU730856C (en) 2001-11-15
EA199800909A1 (ru) 1999-04-29
CN1092658C (zh) 2002-10-16
ES2192264T3 (es) 2003-10-01
PL329880A1 (en) 1999-04-12
DE69720719T2 (de) 2003-11-06
AU730856B2 (en) 2001-03-15
CA2252895A1 (en) 1997-11-13
CO4940465A1 (es) 2000-07-24
NZ332219A (en) 2005-02-25
KR100333214B1 (ko) 2002-06-20
HRP970235A2 (en) 1998-06-30
MY128051A (en) 2007-01-31
CZ349498A3 (cs) 1999-09-15
AR007003A1 (es) 1999-10-13
DE69720719D1 (de) 2003-05-15
AP838A (en) 2000-05-03
AU1936897A (en) 1997-11-26
EP0904273B1 (en) 2003-04-09
HRP970235B1 (en) 2002-08-31
NO985193D0 (no) 1998-11-06
EP0904273A1 (en) 1999-03-31
TR199802241T2 (bg) 1999-02-22
JPH11509865A (ja) 1999-08-31
IS4878A (is) 1998-10-23
ID17504A (id) 1998-01-08
GT199700042A (es) 1998-10-02
IL126590A (en) 2001-11-25
OA10908A (en) 2001-10-26
ZA973875B (en) 1998-11-06
HUP9902808A2 (hu) 2000-03-28
SK150598A3 (en) 2000-03-13
NO985193L (no) 1998-11-06
JP3102896B2 (ja) 2000-10-23
YU49398B (sh) 2005-11-28
TNSN97073A1 (fr) 2005-03-15
YU17397A (sh) 2000-10-30
NO312513B1 (no) 2002-05-21
HU229057B1 (en) 2013-07-29
CZ289216B6 (cs) 2001-12-12
MA26427A1 (fr) 2004-12-20
BG63601B1 (bg) 2002-06-28
DK0904273T3 (da) 2003-07-07
AP9700978A0 (en) 1997-07-31
PL188164B1 (pl) 2004-12-31
KR20000010822A (ko) 2000-02-25
UA47467C2 (uk) 2002-07-15
ME00901B (me) 2005-11-28
CN1216990A (zh) 1999-05-19
HUP9902808A3 (en) 2000-04-28
WO1997042190A1 (en) 1997-11-13
BR9708932A (pt) 1999-08-03

Similar Documents

Publication Publication Date Title
EG24401A (en) Mesylate. Trihydrate of. 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-ine
MA24171A1 (fr) Dihydrates de mesylate de 5- (2- (4-(1,2-benzisothiazole-3-yl) -1-piperazinyl)ethyl) -6-chloro-1,3-dihydro-2h-indole-2-one
AU4600493A (en) Monohydrate of 5-(2-(4-(1,2 benzisothiazol-3-yl) -1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride
ZA972973B (en) Substituted [2-(1-piperazinyl)ethoxy]methyl compounds.
AP9901696A0 (en) Composition comprising 5-(4-(2-(N-methyl-N-2-pyridyl)amino) ehtoxy benzyl)thiazolidine-2,4-dione
ZA974912B (en) Salts of ethyl 3-(2-(4-(4-(amino-imino-methyl)phenyl)-4-methyl-2,5-dioxo-imidazolidin-1-yl)acetylamino)-3-phenyl-propionate.
HU9202914D0 (en) 4-(4-(4-hydroxiphenyl)-1-piperazinyl)-5-methyl-3h-1,2,4-triazole-3-one derivatives
DE69630123D1 (en) Optische spaltung von 1-azabicylo(2.2.2)octan-3-amin,2-(diphenylmethyl)-n-((2-methoxy-5-(1-methylethyl)phenyl)methyl)
HU9802874D0 (en) Process for making 2-(methylthio)-5-(trifluoromethyl)-1,3,4-thiadiazole using methyldithiocarbazinate
ATE525362T1 (de) 2-(3-(4-(2-t-butyl-6-trifluormethylpyrimidin-4-
HUP9802876A3 (en) Process for producing 2-(methylsulfonyl)-5-(trifluoromethyl)-1,3,4-thiadiazole
Khosravan Nonlinear pharmacokinetics of Diltiazem
GB9523212D0 (en) 2-[2-(2,6-Difluoro-phenyl)-1,3,4-thiadiazol-5-yl-oxy]-acetamides
CS10790A2 (en) 2-(4-(2-chlorodibenzo/b,f/thiepin-10-yloxy/ethyl-1-piperazinyl)ethanol and its maleate